MELFOMA® 50
Active ingredient: Melfalan 50 mg (as melfalan hydrochloride)
Dosage form: Lyophilised injection

MELFOMA® 2
Active ingredient: Melfalan 2 mg
Dosage form: Tablets

MELFOMA® 5
Active ingredient: Melfalan 5 mg
Dosage form: Tablets

Argentine Industry

Composition: 

MELFOMA® 50:
Each glass bottle with lyophilised injection contains melfalan 50 mg (as melfalan hydrochloride), and povidone.
Each ampoule with dissolving solution contains sodium citrate, propylene glycol, ethanol 96 %, and water for injection. 

MELFOMA® 2:
Each tablet contains melfalan 2 mg, lactose, corn starch, povidone, and magnesium stearate. 

MELFOMA® 5:
Each tablet contains melfalan 5 mg, lactose, corn starch, povidone, and magnesium stearate. 

Indications: 

MELFOMA® is indicated for the palliative treatment of the multiple myeloma and the ovarian adenocarcicoma non-resectable of epithelial origin. 

Therapeutic action: 

Antineoplastic. 

Storage: 

MELFOMA® lyophilised injection: Keep at temperature between 15º and 30º C, in the marketed packing.
MELFOMA
® tablets: Keep at temperature between 2º and 8º C, in the marketed packing. 

Marketed presentations: 

MELFOMA® lyophilised injection:
Pack containing 1 glass bottle with lyophilised injection + 1 glass bottle with dissolving solution.
Pack containing 100 glass bottles with lyophilised injection + 100 glass bottles with dissolving solution, for use in hospitals. 

MELFOMA® tablets:
Packs containing 25 and 50 tablets.
Pack containing 100 tablets, for use in hospitals. 

Medicinal speciality authorised by the Ministry of Health.
Certificate Nº 51589 

Laboratorio DOSA S.A.
Girardot 1369 (C1427AKC) Buenos Aires, Argentine.
Pharmaceutical Director: María C. Terzo, Pharmacist.